Manila Times Business
Cytokinetics Launches MYQORZO® (aficamten) in European Union, with First Commercial Availability in Germany
European Launch Follows Strong U.S. Start SOUTH SAN FRANCISCO, Calif., and ZUG, Switzerland, June 01, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the first commercial European launch of MYQORZO® (aficamten) in Germany for the treatment of symptomatic (New York Heart Association, NYHA, class II-III) obstructive hypertrophic cardiomyopathy (oHCM) in adult patients. MYQORZO is an allosteric and reversible inhibitor of cardiac myosin motor activity. In patients
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Bonoan rushed to hospital over ‘near stroke’ — Remulla
Just now
TechForce Robotics Enters Pharmaceutical Automation Market Through Initial Deployment at Oncotelic Therapeutics
Just now
BriaCell Presents Positive Clinical Data at ASCO 2026
Just now
Helus Pharma to Participate in the Jefferies Global Healthcare Conference in New York
Just now